secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001493152-25-006481
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 3.03, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas raises $3.3M via Series C preferred and warrants; appoints Dr. Robin Smith to board
--------------------------------------------------------------------------------

- Initial closing of $1.65M for 1,650 Series C shares; second $1.65M closing subject to shareholder approval by April 10, 2025.
- Series C convertible at $0.586/share; warrants exercisable at $0.6446 for 5 years post-shareholder approval.
- Proceeds to reduce operating expenses and explore strategic alternatives for MAT2203 and other options.
- Dr. Robin L. Smith appointed to board; Herbert J. Conrad resigns as founding Chairman and retires.
- Company required to file resale registration statement by 15th day after 2024 10-K filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225006481/0001493152-25-006481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225006481/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-006481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer